News

Temozolomide May Partially Improve Aggressive Pituitary Tumors Causing Cushing’s Disease, Case Study Suggests

The chemotherapy temozolomide partially improved a case of an aggressive pituitary tumor that caused symptoms of Cushing’s disease (CD), according to a new study in Poland. However, after tumor mass and cortisol levels were stabilized for a few months, the patient experienced rapid progression, suggesting that new methods for extending the…

CyberKnife Radiosurgery Effective in Cushing’s Disease, Research Finds

Stereotactic radiosurgery – a type of targeted, high-dose radiation therapy – delivered with CyberKnife technology effectively induces remission in Cushing’s disease patients whose condition persisted after surgical removal of their pituitary glands. However, researchers advise, caution when interpreting the findings. While promising, the study included only a small group of patients analyzed retrospectively.

Laparoscopic Adrenalectomy Is Safe and Effective to Remove Larger Adrenal Tumors, Study Reports

The minimally invasive laparoscopic adrenalectomy (LA) is a safe and feasible procedure for larger adrenal tumors and metastasis, a new Italian study shows. While the findings suggest that the surgical application of laparoscopic adrenalectomy could be extended, surgeons should undergo a 30-procedure learning curve to improve surgical outcomes, researchers say.

Frequent Use of Topical Steroid to Treat Diaper Rash Led to Cushing Syndrome, Case Study Reports

Excessive use of skin-applied steroids to manage diaper rash can lead to an infant developing  Cushing’s syndrome, a case study reports. Cushing’s is characterized by elevated levels of hormones known as glucocorticoids, typically due to malfunctioning of pituitary or adrenal glands. Skin-applied corticosteroid-based therapies, known as topical steriods, are used…

Strongbridge Expecting Second Patent on Cushing’s Treatment Recorlev

Strongbridge Biopharma is expecting a second patent on its Cushing’s syndrome therapy Recorlev (levoketoconazole). The signal it received was the U.S. Patent and Trademark Office completing a review of its new patent application for the cortisol synthesis inhibitor. The second patent, which would expire Jan. 10, 2026, would cover other conditions in…